Skip to main content
Clinical Trials/CTRI/2021/07/034834
CTRI/2021/07/034834
Recruiting
未知

A real-world observational study on Diabetes Mellitus patients administering dual combination therapy of Teneligliptin and MetformIn to evaluate REnal function. - ADMIRE STUDY

Mankind Pharma Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Sponsor
Mankind Pharma Ltd
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female patients, age ââ?°Â¥ 18 to ââ?°Â¤ 85 years.
  • 2\. Uncontrolled Type 2 diabetes with a haemoglobin A1c (HbA1c) ââ?°Â¥7\.0 percent.
  • 3\. eGFR (MDRD) at screening \> 60 mL/min/1\.73m2
  • 4\. Patients who are prescribed Teneligliptin and Metformin combination therapy as part of routine clinical practice.

Exclusion Criteria

  • 1\. Female patients who are pregnant or breast feeding
  • 2\. Patients with known liver or kidney dysfunction
  • 3\. Patients who are suspected of or known to have an intolerance to Teneligliptin or Metformin.
  • 4\. Presence of any other clinically significant disease or laboratory findings that in the Investigators opinion may affect the study outcomes or continued participation of patient in the study.
  • 5\. Participation in another study concurrently or within 4 weeks prior to the Screening Visit

Outcomes

Primary Outcomes

Not specified

Similar Trials